Lumbosacral Radicular Pain Global Market Report 2025

The lumbosacral radicular pain market size has grown strongly in recent years. It will grow from $0.91 billion in 2024 to $0.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be credited to the rising prevalence of lower back disorders, a growing elderly population experiencing spinal problems, an increase in sedentary lifestyles and poor posture, heightened demand for pain management treatments, and greater awareness regarding early diagnosis and intervention.

The lumbosacral radicular pain market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The projected growth in the forecast period can be attributed to advancements in pain management technologies, a growing emphasis on non-opioid treatment alternatives, increased investment in spinal research and development, rising demand for outpatient and minimally invasive procedures, and improved access to healthcare in emerging markets. Key trends expected during this period include progress in minimally invasive surgical techniques, the development of targeted anti-inflammatory medications, innovations in wearable pain management devices, advanced imaging methods for identifying nerve roots, and the creation of personalized treatment plans based on patient-specific data.

The rising prevalence of degenerative spinal conditions is anticipated to drive the growth of the lumbosacral radicular pain market in the coming years. Degenerative spinal conditions encompass a range of disorders resulting from the progressive deterioration of the spine over time. This increase is primarily driven by aging populations and lifestyle factors that contribute to spinal degeneration and nerve compression, leading to greater demand for effective diagnosis and treatment. Lumbosacral radicular pain serves as an indicator of underlying degenerative spinal issues by highlighting nerve root irritation or compression, thereby aiding clinical assessment and treatment planning. For example, in May 2023, the University of Sydney, an Australia-based public university, projected that over 800 million people globally will experience back pain by 2050. As a result, the growing incidence of degenerative spinal conditions is a key factor fueling the expansion of the lumbosacral radicular pain market.

Leading companies in the lumbosacral radicular pain market are prioritizing the development of advanced minimally invasive neuromodulation therapies, including compact and rechargeable spinal cord stimulation (SCS) systems, to improve pain relief and enhance patient comfort. These miniaturized SCS devices are implantable and deliver electrical impulses to the spinal cord to disrupt pain signals, providing extended battery life and less invasive treatment options. For example, in December 2022, Abbott Laboratories, a U.S.-based healthcare company, introduced the Eterna spinal cord stimulation system designed to deliver advanced BurstDR therapy for chronic pain management. This system features state-of-the-art rechargeable battery technology that significantly lengthens the time between recharges, reducing inconvenience for patients. It also includes proprietary stimulation patterns, such as BurstDR, that replicate natural nerve activity for more effective and sustained pain relief. Additionally, the device is MRI-compatible, allowing patients to safely undergo full-body scans without device removal. Its design is also upgrade-friendly, enabling patients to access future technological improvements without requiring further surgeries.

In October 2024, Stryker Corporation, a U.S.-based medical technology company, acquired Vertos Medical Inc. for an undisclosed sum. This acquisition is intended to bolster Stryker’s portfolio of minimally invasive spine treatments by incorporating Vertos Medical’s innovative technologies, improving patient outcomes, and reinforcing its position as a leader in the spinal health market. Vertos Medical Inc. is a U.S.-based company focused on minimally invasive treatments for lumbar spinal stenosis (LSS).

Major players in the lumbosacral radicular pain market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Eli Lilly and Company, Boston Scientific Corporation, Vertex Pharmaceuticals, Biotronik, Nevro Corp., Sorrento Therapeutics, Scilex Holding Company, ProMed Pharma, SPR Therapeutics, Saluda Medical Pty Ltd., Eliem Therapeutics, Cephalon Inc., Semnur Pharmaceuticals Inc., Nalu Medical Inc., Sollis Therapeutics Inc.

North America was the largest region in the lumbosacral radicular pain market in 2024. The regions covered in lumbosacral radicular pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lumbosacral radicular pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lumbosacral radicular pain is a type of pain that begins in the lower spine (lumbar and sacral areas) and travels along the course of a spinal nerve into the leg. It is most often caused by compression or irritation of the nerve root, typically resulting from conditions like a herniated disc or spinal stenosis.

The primary categories of treatment for lumbosacral radicular pain include pharmacological therapies, non-pharmacological approaches, and interventional procedures. Pharmacological therapies involve the use of drugs or medications to diagnose, manage, or prevent health conditions. These medications can be administered through various methods, including oral, topical, injectable, and implantable routes. The distribution of these drugs occurs through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end-users including hospitals, specialty clinics, rehabilitation centers, and homecare environments.

The lumbosacral radicular pain market research report is one of a series of new reports that provides lumbosacral radicular pain market statistics, including the lumbosacral radicular pain industry global market size, regional shares, competitors with the lumbosacral radicular pain market share, detailed lumbosacral radicular pain market segments, market trends, and opportunities, and any further data you may need to thrive in the lumbosacral radicular pain industry. This lumbosacral radicular pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lumbosacral radicular pain market includes revenues earned by entities by providing services such as non-surgical treatment services, interventional pain management services, and rehabilitation and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.